Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Igm Biosciences Inc (IGMS)

Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 477,938
  • Shares Outstanding, K 58,787
  • Annual Sales, $ 2,130 K
  • Annual Income, $ -246,420 K
  • 60-Month Beta 0.26
  • Price/Sales 253.92
  • Price/Cash Flow N/A
  • Price/Book 2.72
Trade IGMS with:

Options Overview Details

View History
  • Implied Volatility 132.31% ( -36.47%)
  • Historical Volatility 97.74%
  • IV Percentile 89%
  • IV Rank 68.27%
  • IV High 176.96% on 10/02/23
  • IV Low 36.23% on 10/10/23
  • Put/Call Vol Ratio 1.83
  • Today's Volume 17
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 673
  • Open Int (30-Day) 570

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.84
  • Number of Estimates 7
  • High Estimate -0.81
  • Low Estimate -0.93
  • Prior Year -1.33
  • Growth Rate Est. (year over year) +36.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.13 +0.70%
on 04/18/24
10.85 -33.87%
on 04/01/24
-3.26 (-31.27%)
since 03/18/24
3-Month
7.13 +0.70%
on 04/18/24
17.70 -59.46%
on 02/20/24
-3.18 (-30.74%)
since 01/18/24
52-Week
3.81 +88.32%
on 11/01/23
17.70 -59.46%
on 02/20/24
-3.43 (-32.31%)
since 04/18/23

Most Recent Stories

More News
Change in Medivir's Board of Directors

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

IGMS : 7.40 (-8.98%)
Fostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cycles

/PRNewswire/ -- Medivir AB (Nasdaq:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 7.40 (-8.98%)
Medivir to present at the Pareto Securities Healthcare Conference

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 7.40 (-8.98%)
Medivir's Partner Tango Therapeutics received FDA clearance to start the TNG348 phase 1/2 clinical study

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 7.40 (-8.98%)
Medivir presents data on additive activity of fostrox in combination with Lenvima or sorafenib in non-clinical tumor models at ILCA

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancers with high unmet medical...

IGMS : 7.40 (-8.98%)
Medivir reports promising interim data, including a first complete response in phase 1b/2a HCC study with fostrox in combination with Lenvima

/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 7.40 (-8.98%)
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 7.40 (-8.98%)
Medivir to present at the Erik Penser Bank Company Event

/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...

IGMS : 7.40 (-8.98%)
Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 7.40 (-8.98%)
Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

/PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...

IGMS : 7.40 (-8.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences...

See More

Key Turning Points

3rd Resistance Point 10.30
2nd Resistance Point 9.84
1st Resistance Point 8.98
Last Price 7.40
1st Support Level 7.66
2nd Support Level 7.20
3rd Support Level 6.34

See More

52-Week High 17.70
Fibonacci 61.8% 12.39
Fibonacci 50% 10.76
Fibonacci 38.2% 9.12
Last Price 7.40
52-Week Low 3.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar